登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002441 证券简称：众业达 公告编号：2026-03 众业达电气股份有限公司 关于注销控股孙公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 为优化投资结构，降低管理成本，提高资产管理效率，众业达电气股份有限公司（以下简称"公司"）于 近期注销了控股子公司成都鸿达新能源科技有限公司全资控股的宜宾鸿达新能源科技有限公司（以下简 称"宜宾鸿达"或"孙公司"）。 一、注销孙公司的基本情况 法定代表人：杨松 注册资本：10万元 成立日期：2018年01月09日 经营范围：科技推广和应用服务业；充电站；电力咨询服务；电子与智能化工程；机械设备、五金产品 及电子产品批发；数字作品的数据库管理；商务信息咨询服务；电气设备修理。 二、对公司的影响 注销完成后，公司合并财务报表的范围将相应发生变化，宜宾鸿达不再纳入公司合并报表范围，不会对 公司整体业务发展和盈利水平产生重大影响，不存在损害上市公司及股东利益的情形。 公司名称：宜宾鸿达新能源科技有限公司 统一社会信用代码：91511500MA690L1Y8 ...

格隆汇2月26日丨众业达(002441.SZ)公布，为优化投资结构，降低管理成本，提高资产管理效率，众业 达电气股份有限公司于近期注销了控股子公司成都鸿达新能源科技有限公司全资控股的宜宾鸿达新能源 科技有限公司（简称"宜宾鸿达"或"孙公司"）。 ...

Group 1 - The core viewpoint of the article is that Zhongyeda Electric Co., Ltd. has recently canceled its wholly-owned subsidiary, Yibin Hongda New Energy Technology Co., Ltd., to optimize its investment structure and improve asset management efficiency [1] Group 2 - The cancellation of Yibin Hongda is part of the company's strategy to reduce management costs [1] - The decision aims to enhance the overall efficiency of asset management within the company [1]

众业达公告称，为优化投资结构、降本增效，公司近期注销控股孙公司宜宾鸿达新能源。该公司由成都 鸿达新能源全资控股，法定代表人杨松，注册资本10万元，2018年1月9日成立。注销完成后，公司合并 财务报表范围相应变化，宜宾鸿达不再纳入，不会对公司业务和盈利水平产生重大影响，也不存在损害 上市公司及股东利益的情形。 ...

Group 1 - The company plans to transfer 30% equity stake in its subsidiary, China-America Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd., through public listing at a minimum price of 1.023 billion yuan [1] - The purpose of the transaction is to optimize the investment structure and maximize asset value, with the final price determined by the public listing results [1][2] - The current ownership structure of China-America Bristol-Myers Squibb includes 60% held by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by the company, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] Group 2 - Bristol-Myers Squibb (China) Investment Co., Ltd. intends to sell its 60% stake in China-America Bristol-Myers Squibb, with a potential buyer expected to submit a confirmation bid by June 2025 for a total acquisition price of 480 million USD, equivalent to 1.44 billion yuan for the company's 30% stake [1] - The company believes that achieving an exit through market-based pricing will better maximize asset value and protect the interests of all shareholders, especially minority shareholders [2]

Group 1 - The core viewpoint of the article is that Shanghai Pharmaceuticals plans to optimize its investment structure by publicly transferring its 30% stake in Celgene Corporation through a public listing, with a minimum listing price of approximately RMB 1.023 billion [1] Group 2 - The transfer process will involve a public listing and must complete relevant state-owned asset evaluation management procedures [1] - The final transfer price will be determined based on the results of the public listing [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) plans to optimize its investment structure and maximize asset value by publicly transferring its 30% stake in Celgene Corporation through a property trading agency, with a minimum listing price of approximately RMB 1.023 billion [1] Group 1 - The company intends to transfer its 30% equity stake in Celgene Corporation [1] - The transfer will be conducted via a public listing process [1] - The minimum listing price is set at approximately RMB 1.023 billion, subject to relevant state evaluation management procedures [1]

Core Viewpoint - The company, Youngor (600177), stated that the reduction of its stake in CITIC Limited was primarily due to foreign exchange management requirements, and it plans to adhere to a prudent investment principle for the recovered funds while continuing to optimize its investment structure [1]. Group 1 - The company reduced its stake in CITIC Limited [1] - The reduction was based on foreign exchange management requirements [1] - The company will continue to optimize its investment structure with the recovered funds [1]

Group 1 - The core viewpoint of the article is that Duori Pharmaceutical (301075.SZ) has recently dissolved its wholly-owned subsidiary, Tibet Chenyun Industrial Co., Ltd., to enhance asset management efficiency, optimize investment structure, and reduce management costs [1] Group 2 - The dissolution of Tibet Chenyun is part of the company's strategy to streamline operations and improve overall financial performance [1]

Investment Structure Optimization - The city aims to optimize investment structure and enhance investment efficiency during the "14th Five-Year Plan" period, with a cumulative investment of nearly 1 trillion yuan and an annual growth rate of around 6%, surpassing national and provincial averages [4] - Focus areas include industrial investment, infrastructure investment, and investments in the livelihood sector, with a target of starting over 350 new industrial projects each year valued at over 100 million yuan [4][5] Industrial Development - The city achieved a 9% growth in industrial added value last year, emphasizing the industrial economy's role as a stabilizing force [5] - Plans for the current year include launching 180 new industrial expansion projects and nurturing over 350 new small and micro enterprises to create more job opportunities [6] Market Stability - The city organized a series of business matching events that generated nearly 10 billion yuan in new orders last year, with a goal of facilitating an additional 10 billion yuan in orders this year [7] - Efforts will continue to enhance policy support and services for enterprises, aiming to reduce corporate burdens by over 20 billion yuan [6][7] Health Sector Development - The city has made significant progress in health and wellness, with an average life expectancy of 82.65 years, exceeding the national average by 3.65 years [8] - Key initiatives include implementing a health-first development strategy, reforming county-level health systems, and enhancing chronic disease management through community health services [8][9] Project Promotion and Foreign Investment - The city recorded 420 projects above 100 million yuan last year, with a target of attracting over 400 new industrial projects valued at over 100 million yuan this year [10] - Strategies include precise project recruitment, enhancing foreign investment channels, and ensuring a growth target of 650 million USD in actual foreign investment [10][11] Lifecycle Management of Projects - A comprehensive project lifecycle management mechanism will be established to ensure high project landing rates, with a target of over 80% for signed projects [11] - The city will optimize its on-site investment promotion efforts, maintaining a stable team of around 500 personnel for effective project management [11]